z-logo
Premium
Expression of CD35 (CR1) and CD11b (CR3) on circulating neutrophils and eosinophils from allergic asthmatic children
Author(s) -
BERENDS C.,
HOEKSTRA M. O.,
DIJKHUIZEN B.,
MONCHY J. G. R.,
GERRITSEN J.,
KAUFFMAN H. F.
Publication year - 1993
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.1993.tb00277.x
Subject(s) - integrin alpha m , receptor , complement receptor , chemotaxis , immunology , receptor expression , n formylmethionine leucyl phenylalanine , granulocyte , allergic inflammation , stimulation , lipopolysaccharide , complement system , medicine , allergy , immune system
Summary Complement receptors on neutrophils and eosinophils play a role in activation and adhesion. During asthmatic reactions these receptors have been found elevated on circulating granulocytes. In the present study we compared the expression of CD35 (complement receptor type 1) and CD11b (complement receptor type 3) on neulrophils and eosinophils from asthmatic and non‐asthmatic children. This was done in whole blood samples using depolarised light scattering for the discrimination of neutrophils and eosinophils. The non‐stimulated expression as well as the upregulaled expression of receptors by the chemotactic peptide N ‐formylmethionyl‐teucyl‐phenylalanine (fMLP) were studied. The results showed that without prior stimulation only the expression of CD35 on neutrophils was significantly elevated in children with asihma ( P < 0.05). After up‐regulation with fMLP. the CD11b expression on neutrophils ( P < 0.005, fMLP: 0.002 μ m ) and eosinophils ( P < 0.05, fMLP: 0.02 μ M) was significantly higher in asthmatic children than in the controls. These results indicate that the inducible expression of CD11b on neutrophils and eosinophils from allergic asthmatic children is primed in rivo .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here